Burden of Uncorrected Myopia on APAC Healthcare Systems
BioSpectrum Asia|BioSpectrum Asia April 2022
Uncorrected myopia remains the leading cause of distance vision impairment globally, and its rising prevalence could cost billions of dollars in lost productivity in the coming decades. A hallmark study by the Brien Holden Vision Institute (BHVI) in Australia predicts that by 2050, over half the world’s population or 52 per cent will be myopic. Moreover, management and control of myopia is a relatively new concept in many countries. Let’s explore what possible steps can be undertaken to address this affliction.
Hamish Thrum
Burden of Uncorrected Myopia on APAC Healthcare Systems

The World Health Organisation (WHO) recently flagged myopia as a global public health issue, estimating annual global costs of productivity losses associated with vision impairment from uncorrected myopia at $244 billion in 2015. This will increase significantly in the future if it is not addressed. Individuals with high myopia (-5.00 diopters or more) face a greater risk of sight-threatening disorders later in life including glaucoma, cataract, retinal detachment, and myopic macular degeneration, which is an irreversible condition that can cause severe vision impairment or permanent blindness. The risk of visual impairment increases 3.4 times with myopia between 6.00 diopters and 10.00 diopters, and 22 times when above 10.00 diopters.

Myopia in the Asia Pacific

Studies have shown the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia.

The early onset and rapid progression of myopia in Asia has been linked to increased time spent on near-work activities and classwork, coupled with limited time spent outdoors; both of which have been exacerbated by the Covid-19 pandemic. According to one Hong Kong study, during the COVID-19 pandemic, the estimated one-year incidence of myopia is 28 per cent, 27 per cent, and 26 per cent for six, seven and eight-year-olds respectively, compared to 17 per cent, 15 per cent, and 15 per cent before the pandemic.

This story is from the BioSpectrum Asia April 2022 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the BioSpectrum Asia April 2022 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Ushering Fourth Industrial Revolution in Telangana
BioSpectrum Asia

Ushering Fourth Industrial Revolution in Telangana

Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).

time-read
6 mins  |
BioSpectrum Asia April 2024
How Indian Biotech Investments are on a Doubling Spree
BioSpectrum Asia

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

time-read
4 mins  |
BioSpectrum Asia April 2024
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
BioSpectrum Asia

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

time-read
5 mins  |
BioSpectrum Asia April 2024
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
BioSpectrum Asia

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

time-read
4 mins  |
BioSpectrum Asia April 2024
Can Test, Treat, Track Beat Malaria?
BioSpectrum Asia

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

time-read
8 mins  |
BioSpectrum Asia April 2024
Engineering CAR T cell sharpshooters
BioSpectrum Asia

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

time-read
6 mins  |
BioSpectrum Asia April 2024
Addressing Challenges in Cell Therapy Manufacturing
BioSpectrum Asia

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

time-read
2 mins  |
BioSpectrum Asia April 2024
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
BioSpectrum Asia

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

time-read
5 mins  |
BioSpectrum Asia April 2024
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
BioSpectrum Asia

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

time-read
10+ mins  |
BioSpectrum Asia April 2024
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024